Lehr C M
Department of Biopharmaceutics and Pharmaceutical Technology, Universität des Saarlandes, Germany.
Crit Rev Ther Drug Carrier Syst. 1994;11(2-3):119-60.
For the efficient delivery of peptides, proteins, and other biopharmaceuticals by nonparenteral routes, in particular via the gastrointestinal, or GI, tract, novel concepts are needed to overcome significant enzymatic and diffusional barriers. In this context, bioadhesion technologies offer some new perspectives. The original idea of oral bioadhesive drug delivery systems was to prolong and/or to intensify the contact between controlled-release dosage forms and the stomach or gut mucosa. However, the results obtained during the past decade using existing pharmaceutical polymers for such purposes were rather disappointing. The encountered difficulties were mainly related to the physiological peculiarities of GI mucus. Nevertheless, research in this area has also shed new light on the potential of mucoadhesive polymers. First, one important class of mucoadhesive polymers, poly(acrylic acid), could be identified as a potent inhibitor of proteolytic enzymes. Second, there is increasing evidence that the interaction between various types of bio(muco)adhesive polymers and epithelial cells has direct influence on the permeability of mucosal epithelia. Rather than being just adhesives, mucoadhesive polymers may therefore be considered as a novel class of multifunctional macromolecules with a number of desirable properties for their use as biologically active drug delivery adjuvants. To overcome the problems related to GI mucus and to allow longer lasting fixation within the GI lumen, bioadhesion probably may be better achieved using specific bioadhesive molecules. Ideally, these bind to surface structures of the epithelial cells themselves rather than to mucus by receptor-ligand-like interactions. Such compounds possibly can be found in the future among plant lectins, novel synthetic polymers, and bacterial or viral adhesion/invasion factors. Apart from the plain fixation of drug carriers within the GI lumen, direct bioadhesive contact to the apical cell membrane possibly can be used to induce active transport processes by membrane-derived vesicles (endo- and transcytosis). The nonspecific interaction between epithelia and some mucoadhesive polymers induces a temporary loosening of the tight intercellular junctions, which is suitable for the rapid absorption of smaller peptide drugs along the paracellular pathway. In contrast, specific endo- and transcytosis may ultimately allow the selectively enhanced transport of very large bioactive molecules (polypeptides, polysaccharides, or polynucleotides) or drug carriers across tight clusters of polarized epi- or endothelial cells, whereas the formidable barrier function of such tissues against all other solutes remains intact.
为了通过非肠道途径,特别是通过胃肠道(GI)有效地递送肽、蛋白质和其他生物药物,需要新的概念来克服显著的酶促和扩散障碍。在这种情况下,生物黏附技术提供了一些新的视角。口服生物黏附给药系统的最初想法是延长和/或加强控释剂型与胃或肠黏膜之间的接触。然而,在过去十年中,使用现有药用聚合物实现这一目的所获得的结果相当令人失望。遇到的困难主要与胃肠道黏液的生理特性有关。尽管如此,该领域的研究也为黏膜黏附聚合物的潜力带来了新的认识。首先,可以确定一类重要的黏膜黏附聚合物——聚丙烯酸,它是蛋白水解酶的有效抑制剂。其次,越来越多的证据表明,各种类型的生物(黏膜)黏附聚合物与上皮细胞之间的相互作用对黏膜上皮的通透性有直接影响。因此,黏膜黏附聚合物可能不仅仅被视为黏合剂,而是一类新型的多功能大分子,具有许多作为生物活性药物递送辅助剂的理想特性。为了克服与胃肠道黏液相关的问题,并在胃肠道内实现更持久的固定,使用特定的生物黏附分子可能能更好地实现生物黏附。理想情况下,这些分子通过类似受体 - 配体的相互作用与上皮细胞自身的表面结构结合,而不是与黏液结合。未来,这类化合物可能在植物凝集素、新型合成聚合物以及细菌或病毒黏附/侵袭因子中找到。除了将药物载体简单固定在胃肠道内,与顶端细胞膜的直接生物黏附接触可能可用于通过膜衍生小泡(内吞和转胞吞作用)诱导主动转运过程。上皮细胞与一些黏膜黏附聚合物之间的非特异性相互作用会导致紧密的细胞间连接暂时松弛,这有利于较小的肽类药物通过细胞旁途径快速吸收。相比之下,特异性的内吞和转胞吞作用最终可能允许非常大体积的生物活性分子(多肽、多糖或多核苷酸)或药物载体选择性地增强穿过极化上皮或内皮细胞紧密簇的转运,而这类组织对所有其他溶质强大的屏障功能仍保持完整。